Nestle reports 84% holding in Aimmune Therapeutics
Nestle reports 84% holding in Aimmune Therapeutics
Société des Produits Nestlé S.A. (SPN), a Nestle(OTCPK:NSRGY)subsidiary announces the results of the tender offer, to purchase all of the outstanding shares of Aimmune Therapeutics'(NASDAQ:AIMT)common stock for $34.50/share. The offer expired on October 9.
雀巢(OTCPK：NSRGY)子公司法国兴业银行(Sociétédes Produits NestléS.A.)宣布要约结果，将购买雀巢的全部流通股免疫治疗学(纳斯达克股票代码：AIMT)普通股价格为每股34.50美元。该报价已于10月9日到期。
Equinity Trust Company, the depositary for the offer, has advised Nestlé that, 43,435,583 shares were validly tendered and not withdrawn, which represents, ~84% of the outstanding shares as of the Expiration Date.
此次要约的托管人Equity Trust Company已通知雀巢，43,435,583股股票已被有效投标，未被撤回，这相当于截至到期日流通股的约84%。
See below overview of Nestle business over past 150 years:
以下是雀巢在过去150年的业务概况：
Previously: Nestle to buy Aimmune Therapeutics for $2.6B (Aug. 31)
前情：雀巢将以26亿美元收购AImmune Treeutics(8月31日)
Click to subscribe to real-time analytics on NSRGY
单击以订阅NSRGY上的实时分析
Now read:Merger Arbitrage Analysis And Spread Performance - October 11, 2020 »
现在请阅读：合并套利分析和价差表现-2020年10月11日»